Key result
Simvastatin co-administration reduced 5-fluorouracil-induced mortality from 60% to 28% and significantly ameliorated ECG abnormalities, cardiac stress biomarkers, and histopathological lesions.
Why the study?
5-Fluorouracil is associated with rare, serious cardiotoxicity, but the involvement of ROCK/NF-κB, Akt/eNOS, and ET-1/ERK1/2 pathways in this toxicity and in the potential cardioprotective effect of simvastatin has been elusive.
Does simvastatin prevent 5-fluorouracil-induced cardiotoxicity in a rat model?
Does simvastatin prevent 5-fluorouracil-induced cardiotoxicity in a rat model?
Absolute Event Rate: 28% vs 60%
p-value: p=<0.05
Simvastatin demonstrates potential cardioprotective effects against 5-fluorouracil-induced cardiotoxicity in rats by modulating ROCK/Akt/eNOS and ET-1/ERK pathways.
Supports statin cardioprotection in rat 5-FU cardiotoxicity; leaves open human translation.
5-Fluorouracil (5-FU) is used in the treatment of different solid tumors; however, its use is associated with rare, but serious cardiotoxicity. Nevertheless, the involvement of ROCK/NF-κB, Akt/eNOS and ET-1/ERK1/2 trajectories in the cardiotoxic effect and in the potential cardioprotective upshot of simvastatin has been elusive. Male Wistar rats were allocated into 5-FU (50 mg/kg/week; i.p, 6 weeks), simvastatin (15 mg/kg/day; p.o, 8 weeks) treated groups and simvastatin + 5-FU, besides the normal control group. 5-FU-induced cardiotoxicity boosted the serum level of N-terminal pro-brain (B-type) natriuretic peptide (NT-proBNP), aortic contents of endothelin (ET)-1 and thromboxane (TX) A2, as well as cardiac contents of NADPH oxidases (Nox), cyclooxygenase (COX)-2, malondialdehyde (MDA), phosphorylated Akt (p-Akt), phosphorylated extracellular signal-regulated kinase (p-ERK)1/2 and the protein expressions of rho-kinase (ROCK) and caspase-3. On the other hand, it suppressed cardiac reduced glutathione (GSH) and phosphorylated endothelial nitric oxide synthase (p-eNOS). Contrariwise, co-administration with simvastatin overcame these disturbed events and modulated the ROCK/NF-κB, Akt/eNOS and ET-1/ERK1/2 signaling pathways. This study highlights other mechanisms than coronary artery spasm in the 5-FU cardiotoxicity and reveals that NT-proBNP is a potential early marker in this case. Moreover, the cross-talk between ROCK/ NF-κB, ROS/COX-2/TXA2, Akt/eNOS and ET-1/ERK1/2 pathways contributes via different means to upsetting the vasoconstriction/vasodilatation equilibrium as well as endothelial cell function and finally leads to cardiomyocyte stress and death-the modulation of these trajectories offers simvastatin its potential cardio-protection against 5-FU.
No takes yet. Share an insight, caveat, or question.
Muhammad et al. (2020) studied 5-Fluorouracil-induced cardiotoxicity (n=80). Simvastatin vs. 5-Fluorouracil alone was evaluated on Mortality (p=<0.05). Simvastatin co-administration reduced 5-fluorouracil-induced mortality from 60% to 28% and significantly ameliorated ECG abnormalities, cardiac stress biomarkers, and histopathological lesions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: